• Shattuck Labs outlined strategy pivot toward inflammatory and immune-mediated diseases, centered on DR3 blocking antibodies targeting TL1A/DR3 pathway.
• Lead asset SL-325 positioned as potentially first-in-class DR3 blocking antibody, with Phase 2 development planned in Crohn’s disease; Phase 1 enrollment in healthy volunteers completed with data expected in Q2 2026.
• Presentation highlighted rationale for DR3 targeting versus TL1A blockade, citing stable DR3 expression, potential for more durable pathway inhibition, and expectation of lower immunogenicity risk from reduced immune complex formation.
• Cash and cash equivalents reported at $90.4 million as of March 31, 2026; cash runway projected into 2029 assuming receipt of $51.5 million from full exercise of outstanding common.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.